Investigators Still Seeking Options Beyond PARP Inhibitors in Ovarian Cancers
Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.
Source: OncLive